Information Provided By: 
Fly News Breaks for April 20, 2015
MDVN
Apr 20, 2015 | 06:35 EDT
Credit Suisse assumed coverage on Medivation with a Neutral rating from an Outperform rating and increased its price target to $115 from $98. The firm's survey suggests a strong uptake for Xtandi but at a shorter duration than anticipated in the pre-chemo setting and views valuation as stretched following the 30% run in the past two months.
News For MDVN From the Last 2 Days
There are no results for your query MDVN
